瑞舒伐他汀对晚期支架贴壁不良影响.docVIP

瑞舒伐他汀对晚期支架贴壁不良影响 　　 　　 　　[摘要] 目的 研究瑞舒伐他汀与晚期支架贴壁不良的相关性。 方法 选取63例患者，将其分为治疗组和对照组，其中治疗组35例，支架置入术前后持续口服瑞舒伐他汀10 mg，1次/d，至复查造影时；对照组28例，支架置入术前后不服或服用瑞舒伐他汀10 mg，1次/d，总时间少于4周。两组患者支架置入后即刻行血管内超声检查（IVUS），且在支架置入后6～9个月复查IVUS和冠状动脉造影。两次住院期间均检测血清高敏C-反应蛋白（hs-CRP）和低密度脂蛋白胆固醇（LDL-C）。 结果 治疗组有3例患者发生晚期支架贴壁不良，共计4个部位；对照组为8例，共13个部位；两组差异有统计学意义（P0.05）。治疗组血管外弹力膜增加面积、中膜增加面积、管腔减少面积、内膜增生横截面积均小于对照组，差异有统计学意义（P0.05）。治疗组两次住院期间hs-CRP和LDL-C水平的变化显著优于对照组（P0.01）。 结论 瑞舒伐他汀能够降低晚期支架贴壁不良的发生率，减轻非特异性炎症反应，降低LDL-C水平。 　　[关键词] 瑞舒伐他汀；支架贴壁不良；血管内超声；高敏C-反应蛋白；低密度脂蛋白胆固醇 　　[中图分类号] R972[文献标识码] A[文章编号] 1674-4721（2014）04（c）-0099-03 　　 　　The effect of rosuvastatin on late stent malapposition 　　ZHANG Hong-yu LI Min XU Chun-dong 　　Department of Cardiology,the Central Hospital of Jilin City in Jilin Province,Jilin 132011,China 　　[Abstract] Objective To investigate the correlation between rosuvastatin and late stent malapposition (LSM).Methods 63 cases of patients were divided into treatment group and control group,35 patients in treatment group were continuously taken rosuvastatin administration 10 mg qd before and after percutaneous coronary implantation (PCI).28 patients in control group were not taken rosuvastatin or taken rosuvastatin administration 10 mg qd less than 4 weeks.All cases were performed intravascular ultrasound (IVUS) immediately after PCI.And they were reexamined IVUS and angiography in 6-9 month after PCI.Serum high-sensitivity C-reactive protein (hs-CRP) and low density lipoprotein cholesterol (LDL-C) were tested during in-hospital.Results Three patients appeared LSM in treatment group,a total of 4 places.By contrast,eight patients were examined LSM in control group,a total of 13 places;two groups had significant difference (P0.05); Increase the area of the external elastic membrane,the membrane increase the area,reducing the area of the lumen,intimal hyperplasia cross-sectional area in treatment group was less than that of the control group respectively (P0.05).The changes of hs-CRP and LDL-C levels